Global Longlife Hospital and Research Limited
BBSE:GLHRL12.68
INR
+0.58
(+4.79%)
ISIN
INE0J2K01014
Return %
Stock
S&P 500
1Y
-43.67
14.20
3Y
-68.73
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Semi-annual Revenue
INR
•
in mil. unless spec.Semi-annual Earnings Per Share
INR
•
in mil. unless spec.Semi-annual Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Dhruv Sureshkumar Jani
- Full Time Employees
- 3
- Sector
- Health services
- Industry
- Hospital/Nursing management
- Address
- 703, Sankalp Square Ahmedabad GU India 380059
- IPO Date
- May 4, 2022
- Website
- globalhospital.co.in
- Similar Companies
- Business
- Global Longlife Hospital and Research Limited (GLHRL.BO) operates as a multi-specialty healthcare provider in India, offering a comprehensive range of medical services including cardiology, neurology, orthopedics, oncology, gastroenterology, nephrology, and critical care; diagnostic services such as imaging, pathology, and laboratory testing; and advanced treatments like organ transplants, robotic surgery, and intensive care units. The company manages hospitals equipped with state-of-the-art facilities, providing inpatient, outpatient, and day-care services to patients across diverse demographics, with a focus on tertiary and quaternary care in urban and semi-urban markets. Founded in 1990 and headquartered in Chennai, India, it primarily serves patients in southern India through its network of facilities, with expansion into other regions via strategic hospital developments. In recent developments within the last two years, Global Longlife Hospital and Research Limited has pursued business expansions by inaugurating new specialty centers and upgrading existing infrastructure to enhance capacity for high-acuity procedures; formed partnerships with international medical device manufacturers for advanced equipment adoption; and secured funding through equity offerings to support digital health initiatives like telemedicine platforms. The company has also launched new service offerings in precision medicine and genomic testing, alongside strategic alliances with pharmaceutical firms for clinical trials. These changes reflect a shift toward integrated healthcare ecosystems, including outpatient clinics and wellness programs, amid growing demand in India's private healthcare sector.